The new oral anti-viral drug Molnupiravir is rapidly gaining interest as it seems to be effective against SARS-CoV-2. Originally developed as part of a project targeting Venezuelan equine encephalitis virus at Emory University in Atlanta, the drug demonstrated efficacy against various RNA viruses, such as influenza, Ebola, chikungunya, and coronaviruses, and clinical trials for treatment of influenza began in 2019. By early 2020 research was redirected to look into the drug’s efficacy against SARS-CoV-2 and the drug was licensed to bigger pharmaceutical companies for further investigation, Ridgeback Biotherapeutics who eventually partnered with Merck & Co. Molnupiravir has demonstrated promising results but has not yet been approved by the United States’ FDA (Food and Drug Administration) or any other regulatory body, however we have already seen extensive use of ground-breaking vaccines during the pandemic, yet the virus rolls on. Could antiviral drug, Molnupiravir, help end the pandemic?